NTP-CARVEDILOL TABLET

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CARVEDILOL

Dostopno od:

TEVA CANADA LIMITED

Koda artikla:

C07AG02

INN (mednarodno ime):

CARVEDILOL

Odmerek:

25MG

Farmacevtska oblika:

TABLET

Sestava:

CARVEDILOL 25MG

Pot uporabe:

ORAL

Enote v paketu:

100/500

Tip zastaranja:

Prescription

Terapevtsko območje:

BETA-ADRENERGIC BLOCKING AGENTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0122683001; AHFS:

Status dovoljenje:

CANCELLED PRE MARKET

Datum dovoljenje:

2015-08-06

Lastnosti izdelka

_ _
_Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 35_
_ _
_ _
_ _
_ _
PRODUCT MONOGRAPH
Pr
NTP-CARVEDILOL
(carvedilol tablets)
3.125 mg, 6.25 mg, 12.5 mg, 25 mg
Congestive Heart Failure Agent
TEVA CANADA LIMITED
30 Novopharm Court
Toronto, Canada
M1B 2K9
Date of Preparation:
July 12, 2013
Control #: 165863
_ _
_Product Monograph _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
.........................................................................................